Thus, in addition to testing CAMKK2’s role in an aggressive prostate cancer GEMM, we sought to simultaneously assess its impact on systemic metabolism to determine if targeting CAMKK2 could be dually beneficial in both treating the tumor and its linked comorbidities (Overview of approach—Supplemental Figure S1). The gene discussed is CAMKK2; the disease is Familial prostate cancer.